The Uromigos

Episode 213: IL-15RaFc superagonist in NMIBC 09.01.2023 23:27 ↓

Sam Chang describes the data for this agent in bladder cancer. 

Episode 212: What's coming in GU Cancers in 2023 02.01.2023 36:11 ↓

What's happening this year in GU cancer. 

Episode 211: CAR-T cell therapy in RCC 29.12.2022 29:56 ↓

Monty Pal describes his recent study presented at SITC. 

Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients 22.12.2022 26:04 ↓

Dan George and Silke Gillessen disagree amicably. 

Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer 17.12.2022 28:11 ↓

Matt Galski defends cisplatin admirably. 

Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer 12.12.2022 34:09 ↓

David McDermott and Brian Rini debate this topic.

Episode 207: Editorial on COSMIC-313 05.12.2022 29:25 ↓

Pavlos Msaouel discusses some of the statistical components of this and other RCC studies. 

Episode 206: Dan Shapiro in the Rising Star series 28.11.2022 18:17 ↓

Dan talks about his work in rare renal cancer. 

Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer 21.11.2022 23:07 ↓

Andrea Necchi describes his paper and the future of this combination. 

Episode 204: Scott Haake in the Rising Star series 14.11.2022 23:06 ↓

Scott discusses ctDNA in RCC. 

Episode 203: Renee Saliby in the Rising Star series 14.11.2022 20:58 ↓

Validating the Immotion151 Signatures

Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC 07.11.2022 23:06 ↓

Axel Merseburger describes the results of this randomised trial in Lancet Oncology. 

Episode 201: PARPi in CRPC 01.11.2022 27:47 ↓

Rob Jones gives his views on the current data sets. 

Episode 200: Chromophobe renal cancer 25.10.2022 20:42 ↓

Lisa Henske discusses her latest paper on the biology of the disease. 

Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer 17.10.2022 24:57 ↓

Randomised trial of rogaratinib in bladder cancer with Cora Sternberg. 

Episode 198: The RADICALS trial in prostate cancer 07.10.2022 24:10 ↓

Silke Gillessen and Nick James discuss the results of this randomised trial exploring duration of adjuvant/salvage androgen ablation with XRT in prostate cancer. 

Episode 197: The Uromigos Nashville 2022 29.09.2022 9:42 ↓

Here are the details for the Livestream portions of The Uromigos Nashville meeting!  Bladder Cancel Panel on September 30, 1-2PM CST https://youtu.be/yzYkYZbCguE   Prostate Cancer on October 1, 10-11AM CST https://youtu.be/WghMP5kcqxQ RCC Panel on October 1, 2-3PM CST https://youtu.be/4-DQ6lghQ2o

Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer 14.09.2022 32:22 ↓

Toni Choueiri describes the study. 

Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer 13.09.2022 20:25 ↓

Peter O'Donnell describes the study. 

Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer 12.09.2022 24:35 ↓

Nizar Tannir describes this randomised phase 3 study presented at ESMO. 

Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer 11.09.2022 19:31 ↓

Rahul Aggarwal describes the results of this randomised phase III study. 

Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials 11.09.2022 28:27 ↓

Axel Bex summarises the ipi/nivo, pembro and atezo studies. 

Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC 10.09.2022 26:05 ↓

Mohamed Allaf describes the results of this study from ESMO. 

Episode 190: ESMO 2022 Preview 02.09.2022 24:45 ↓

Chris Sweeney joins us to talk about potential highlights.

Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy 22.08.2022 23:38 ↓

John Kelly describes the benefits of robotic surgery.